Tissue Regeneration Technologies: 251 Heritage Walk Woodstock, GA 30188|(404) 402-6844
Woodstock, GA, August 24, 2012 -- TISSUE REGENERATION TECHNOLOGIES, LLC today announced that that the U.S. Patent and Trademark Office will issue the Company patent number 8257282 on September 4, 2012. The patent will cover an apparatus for generating pressure pulse/shock waves utilizing TRT’s unfocused, Softwave™ technology.
The patent will comprise shock wave fronts having plane, nearly plane, convergent off target and/or divergent characteristics, and thus will embody a wide range of unfocused shock wave technologies and utilizations.
John Warlick, CEO of TRT, described the patent issuance’s importance on the company’s ever-expanding intellectual property portfolio. “This latest patent is critically important to TRT and a milestone in that it will protect our unfocused shock wave – Softwave™ – franchise,” he said. “This broad patent for our unfocused technology for the treatment of tissue is invaluable in helping to develop and protect our Softwave™ technology.”
“This patent is our first device patent that protects our parabolic lens design as well as unfocused, defocused, and divergent configurations,” Warlick continued.
TRT’s intellectual property portfolio now numbers 21 medical technology patents and remains at the forefront of the industry.
About Softwave™ Technology
Tissue Regeneration Technologies’ Softwave™ technology comprises multiple uses for unfocused shock waves.
TRT’s patented unfocused Softwaves™ are distinguished from competitors’ technology in that Softwaves™ use a parabolic, rather than an ellipsoid, reflector in the shock wave therapy head. This allows delivery of unfocused waves of acoustic energy over a broad, rather than narrow, target area.
Unfocused shock waves are proven to recruit a patient’s own stem cells to any treatment location and greatly increase vascularization. Pathologies that benefit from Softwave™ technology include acute and chronic wounds, heart ischemia, plantar fasciitis and other pain indications, and non-healing fractures.
SoftWave™ technology is less painful (i.e. anesthesia free), has a higher efficacy rate, faster treatment times, and fewer required retreatments than competitors’ focused shock wave systems.
About Tissue Regeneration Technologies
TRT is an international medical device company established to develop, manufacture and sell SoftWave™ acoustical pressure pulse devices to treat various conditions poorly served by the current standard of care.
TRT is headquartered in Woodstock, Georgia, while production of TRT’s devices is handled by its manufacturing subsidiary, MTS Europe GmbH, which is located in Konstanz, Germany.
TRT is currently conducting an FDA trial for its DermaGold™ device for the treatment of wounds. TRT has FDA clearance to market its LithoGold™ lithotripsy system for the treatment of kidney and urethral stones. TRT devices are CE approved and distributed in approximately 20 countries worldwide.